Current Report Filing (8-k)
May 23 2017 - 5:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported)
May 18, 2017
LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)
Nevada
|
000-52138
|
20-2000871
|
(State or other jurisdiction of
|
(Commission File Number)
|
(IRS Employer
|
incorporation)
|
|
Identification No.)
|
156 Valleyview Road, Kelowna, BC Canada
|
V1X 3M4
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrants telephone number, including area code
(250) 765-6424
N/A
(Former name or former address, if
changed since last report.)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 3.02
Unregistered Sales of Equity Securities
On May 19, 2017, Lexaria Bioscience Corp. (the Company or
Lexaria) received US$970,230.05
from the exercise of warrants
previously granted. The stock warrants, which otherwise expired on May 15 2017,
were exercised at the price of US$0.2273, for a total of 4,268,500 common shares
being issued. All warrants are being exercised by third parties who are neither
officers nor directors of the Company.
Following issuance of these common
shares, Lexaria will have 66,506,009 common shares issued and outstanding. No
commissions or placement fees have been paid related to the funds received from
this warrant exercise. Proceeds will be used for general corporate purposes.
Lexaria extends its thanks to its loyal shareholders for their continued
support.
The securities referred to herein will not be or have not
been registered under the United States Securities Act of 1933, as amended, and
may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements.
- 2 -
Item 7.01
Regulation FD Disclosure
A copy of the news release announcing that Lexaria will
featured on a special BTV episode exploring burgeoning cannabis enterprises and
a news release announcing that Lexaria has received US$970,230.05
from
the exercise of warrants previously granted., are filed are exhibits 99.1 and
99.2 respectively, to this current report and is hereby incorporated by
reference.
Item 9.01
Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
|
|
|
|
/s/ Chris
Bunka
|
|
Chris Bunka
|
|
CEO, Principal Executive Officer
|
|
|
|
Date: May 18, 2017
|
|